Related Experiment Video
Updated: Nov 5, 2025
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylase 10, a potential epigenetic target for therapy
Fajuan Cheng1,2, Bin Zheng3,4,5, Jianwei Wang6
1Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China.
Abstract:
Histone deacetylase (HDAC) 10, a class II family, has been implicated in various tumors and non-tumor diseases, which makes the discovery of biological functions and novel inhibitors a fundamental endeavor. In cancers, HDAC10 plays crucial roles in regulating various cellular processes through its epigenetic functions or targeting some decisive molecular or signaling pathways. It also has potential clinical utility for targeting tumors and non-tumor diseases, such as renal cell carcinoma, prostate cancer, immunoglobulin A nephropathy (IgAN), intracerebral hemorrhage, human immunodeficiency virus (HIV) infection and schizophrenia. To date, relatively few studies have investigated HDAC10-specific inhibitors. Therefore, it is important to study the biological functions of HDAC10 for the future development of specific HDAC10 inhibitors. In this review, we analyzed the biological functions, mechanisms and inhibitors of HDAC10, which makes HDAC10 an appealing therapeutic target.
Insights
Histone deacetylase 10 (HDAC10) is crucial in various diseases, including cancers. Understanding its functions and developing specific inhibitors is vital for new therapeutic strategies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Histone deacetylase 10 (HDAC10), a class II enzyme, is implicated in numerous tumor and non-tumor diseases.
- Its roles in epigenetic regulation and signaling pathways are critical in cellular processes.
Purpose of the Study:
- To review the biological functions, mechanisms, and inhibitors of HDAC10.
- To highlight HDAC10 as a potential therapeutic target for various diseases.
Main Methods:
- Literature review of studies on HDAC10.
- Analysis of HDAC10's involvement in cancer and non-cancerous conditions.
- Examination of existing and potential HDAC10 inhibitors.
Main Results:
- HDAC10 plays significant roles in cancer progression and non-tumor diseases like IgA nephropathy and HIV infection.
- Few specific HDAC10 inhibitors have been developed to date.
- HDAC10's diverse functions make it a promising target for drug development.
Conclusions:
- HDAC10 is a key therapeutic target for both oncological and non-oncological conditions.
- Further research into HDAC10 biology and inhibitor development is warranted.
- Targeting HDAC10 offers potential clinical utility across a spectrum of diseases.
Related Concept Videos
02:32Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
02:32Histone Modification
02:25Spreading of Chromatin Modifications
Writers
The writer...
01:37Epigenetic Regulation
X-chromosome...
01:46Epigenetic Regulation
01:32Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...